While the presence of diagnoses such as LADA or longstanding T2DM where insulin therapy is needed does not necessarily preclude patients from using SGLT2i, they should at least prompt judicious counseling and monitoring. This evidence concerns the gene INS and type 2 diabetes mellitus.